Across TCGA pan-cancer cohorts, GNGT2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of GNGT2’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where GNGT2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GNGT2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.
LSCC and LUAD are the cancer types where GNGT2 tumor–normal differential expression is most reproducible.